Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,021 recruiting studies in this area right now.
By phase
- Not applicable2,807
- Phase 2752
- Phase 1522
- Phase 3382
- Phase 1/Phase 2294
- Phase 4205
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,192
- Melanoma175
- Metastatic Breast Cancer138
- Rheumatoid Arthritis132
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Breast Neoplasms111
- Triple Negative Breast Cancer111
- Colorectal Cancer94
- Ovarian Cancer92
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer59
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Novartis Pharmaceuticals49
- Memorial Sloan Kettering Cancer Center48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University35
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California406
- Arizona152
- Alabama129
- Florida126
- New York111
- Texas106
- Maryland95
- Massachusetts88
- Pennsylvania72
- North Carolina67
Recruiting studies5,021 total
- NCT05804916RecruitingPhase 2/Phase 3
Tracking-guided radiation for left breast after surgery
This trial tests a radiation planning and monitoring approach that uses surface tracking and breathing control to deliver large-area radiation more accurately for left breast cancer. It may help improve how consistently treatment is delivered while accounting for chest movement.
Beijing, Beijing MunicipalityAges 18–70 - NCT05212454RecruitingPhase 3
Capecitabine added after surgery for high-risk ER-positive breast cancer
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
Hanzhou, ZhejiangAges 18–70 - NCT05452213RecruitingPhase 4
Study patterns of ribociclib response and resistance in breast cancer
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
Erlangen, BavariaAges 18 years+ - NCT05588583Recruiting
Tracking drainage from chronic leg or foot ulcers with a dressing
This study follows how much fluid (drainage) a chronic ulcer produces over time using a dressing called Mepilex Up. It may help clinicians better understand how this dressing manages “exuding” ulcers on the leg or foot.
Castro Valley, CaliforniaAges 18 years+ - NCT04800393Recruiting
Breast surgery anesthesia and its effects on immunity and survival
This study compares two ways of giving anesthesia during breast cancer surgery to see how they affect the immune system and outcomes after surgery. It may help identify which anesthesia approach is better for people like you having early-stage, operable breast cancer surgery.
MoscowAges 45–74 - NCT05832580RecruitingPhase 3
Preventing calcium buildup in skin, eyes, and blood vessels
This Phase 3 study tests a medicine to help prevent abnormal calcium (called ectopic mineralization) from building up in people with pseudoxanthoma elasticum (PXE). It aims to slow or reduce new damage over time.
UtrechtAges 18–50 - NCT05833659Recruiting
Comparing two breast reconstruction positions after mastectomy
This trial compares two surgical techniques for breast reconstruction: placing the implant under the chest muscle versus in front of it. It may help people understand which approach works better for comfort and healing after mastectomy.
Beijing, Beijing MunicipalityAges 18–70 - NCT05835739Recruiting
Study of breast cancer prevention in BRCA1/2 mutation carriers
This is an observational study that looks at how different cancer prevention approaches affect women with harmful (deleterious) BRCA1 or BRCA2 mutations. It may help improve future prevention and follow-up plans for women at higher inherited risk.
Aviano, PordenoneAges 18 years+ - NCT05851014RecruitingPhase 3
GB491 plus letrozole for HR+ HER2- advanced breast cancer
This Phase 3 study tests whether GB491 used together with letrozole works better for hormone receptor–positive and HER2-negative advanced breast cancer. You may be eligible if you have not had certain prior cancer treatments and your health tests are within safe limits.
Bengbu, AnhuiAges 18–75 - NCT04218422Recruiting
Battlefield-style ear acupuncture for hidradenitis pain
This trial tests a type of ear acupuncture (“battlefield acupuncture”) to reduce pain from hidradenitis suppurativa, a long-term skin condition. You may be eligible if your hidradenitis pain is frequent and your treatments are stable.
Dearborn, MichiganAges 18 years+ - NCT05795335Recruiting
Testing CDK4/6 medicines for advanced hormone-positive breast cancer
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05440240RecruitingPhase 4
Needling and possibly steroid shot for Dupuytren’s hand tightness
This trial tests a minimally invasive procedure that uses a needle to release tight tissue in the hand, and may include a steroid injection. It aims to improve hand finger straightening for people with Dupuytren’s contracture.
SilkeborgAges 45–99 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05876416Recruiting
Study genetics of rare bone growth disorders
This study looks at genetic causes of skeletal (bone growth) disorders in people who show signs based on height and bone imaging. Genetic testing may help explain what’s behind the condition, especially when it seems inherited.
StockholmAges Any age - NCT05890092Recruiting
Study of vulvar diseases in Nigeria
This is an observational study that looks at vulvar conditions in people assigned female at birth in Nigeria. It does not test a new treatment—researchers mainly want to learn about different vulvar diseases and who gets them.
LondonAges 10–90 - NCT04020575RecruitingPhase 1
CAR T cells made from your blood for advanced breast cancer
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
Duarte, CaliforniaAges 18 years+ - NCT04979078Recruiting
Light therapy to ease chemotherapy hand-foot skin reaction
This study tests whether a light-based therapy (photobiomodulation) can reduce pain and skin irritation from hand-foot syndrome/hand-foot skin reaction in people getting chemotherapy or targeted medicines. It may help you heal sooner and feel more comfortable while treatment continues.
Hasselt, LimburgAges 18 years+ - NCT05058183Recruiting
Testing shorter chemotherapy for early HER2 or triple‑negative breast cancer
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
LondonAges 18 years+ - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT05916755Recruiting
Testing tumor clues that predict response to immunotherapy
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
BarcelonaAges 18 years+ - NCT05253872Recruiting
Danish study to track early melanoma after surgery
This study tests a new way to monitor people after surgery for early-stage melanoma. If you qualify, it may help your doctors watch for changes sooner or more accurately during follow-up.
CopenhagenAges 18 years+ - NCT05883371Recruiting
IMPACT autoimmune study registry for people on biologic medicines
This study is a registry that collects health information from adults with certain autoimmune conditions who are currently using (or have been recommended) biologic or DMARD medicines. It may help researchers better understand these diseases and how treatments affect people over time.
Columbus, OhioAges 18–70 - NCT05665556Recruiting
Registry for pulmonary hypertension in connective tissue disease
This trial is a registry that collects health information from people with certain types of pulmonary hypertension linked to connective tissue diseases. It helps doctors understand patterns of disease and outcomes, which can guide future care and studies.
Mexico CityAges 18 years+ - NCT05570227Recruiting
Study metabolism in melanoma using a glucose tracer
This study looks at how melanoma cells and the body use sugar by collecting tissue samples and, for some people, giving a labeled glucose infusion. It may help researchers understand melanoma “metabolic” patterns and how they relate to cancer behavior.
Melbourne, VictoriaAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,021 recruiting dermatology studies from the U.S. registry right now, out of 7,720 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.